Click here to view and claim credit for Managing Toxicities of Novel Breast Cancer Therapies: PI3K Inhibitors, an accredited CME/NCPD/CPE activity by i3 Health: i3health.com/odabc-pi3k.

Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke’s Koontz Center for Advanced Breast Cancer, shares updated strategies for managing these toxicities in order to provide the best outcomes for patients with breast cancer receiving PI3K inhibitors.

Additional Advances in PI3K Inhibitor Research & Clinical Trials With Janie Metsker, RN, BSN, CN-BN

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Additional Advances in PI3K Inhibitor Research & Clinical Trials With Janie Metsker, RN, BSN, CN-BN

Oncology Data Advisor®